» Articles » PMID: 31944571

Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Using a Deep Learning (DL) Method

Overview
Journal Thorac Cancer
Date 2020 Jan 17
PMID 31944571
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The aim of the study was to develop a deep learning (DL) algorithm to evaluate the pathological complete response (pCR) to neoadjuvant chemotherapy in breast cancer.

Methods: A total of 302 breast cancer patients in this retrospective study were randomly divided into a training set (n = 244) and a validation set (n = 58). Tumor regions were manually delineated on each slice by two expert radiologists on enhanced T1-weighted images. Pathological results were used as ground truth. Deep learning network contained five repetitions of convolution and max-pooling layers and ended with three dense layers. The pre-NAC model and post-NAC model inputted six phases of pre-NAC and post-NAC images, respectively. The combined model used 12 channels from six phases of pre-NAC and six phases of post-NAC images. All models above included three indexes of molecular type as one additional input channel.

Results: The training set contained 137 non-pCR and 107 pCR participants. The validation set contained 33 non-pCR and 25 pCR participants. The area under the receiver operating characteristic (ROC) curve (AUC) of three models was 0.553 for pre-NAC, 0.968 for post-NAC and 0.970 for the combined data, respectively. A significant difference was found in AUC between using pre-NAC data alone and combined data (P < 0.001). The positive predictive value of the combined model was greater than that of the post-NAC model (100% vs. 82.8%, P = 0.033).

Conclusion: This study established a deep learning model to predict PCR status after neoadjuvant therapy by combining pre-NAC and post-NAC MRI data. The model performed better than using pre-NAC data only, and also performed better than using post-NAC data only.

Key Points: Significant findings of the study. It achieved an AUC of 0.968 for pCR prediction. It showed a significantly greater AUC than using pre-NAC data only. What this study adds This study established a deep learning model to predict PCR status after neoadjuvant therapy by combining pre-NAC and post-NAC MRI data.

Citing Articles

An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer.

Gao Y, Ventura-Diaz S, Wang X, He M, Xu Z, Weir A Nat Commun. 2024; 15(1):9613.

PMID: 39511143 PMC: 11544255. DOI: 10.1038/s41467-024-53450-8.


Combining Biology-based and MRI Data-driven Modeling to Predict Response to Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

Stowers C, Wu C, Xu Z, Kumar S, Yam C, Son J Radiol Artif Intell. 2024; 7(1):e240124.

PMID: 39503605 PMC: 11791743. DOI: 10.1148/ryai.240124.


Predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer using a machine learning approach.

Zhao F, Polley E, McClellan J, Howard F, Olopade O, Huo D Breast Cancer Res. 2024; 26(1):148.

PMID: 39472970 PMC: 11520773. DOI: 10.1186/s13058-024-01905-7.


Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer.

Kim S, Lee J, Cho N, Kim Y Sci Rep. 2024; 14(1):23065.

PMID: 39367159 PMC: 11452398. DOI: 10.1038/s41598-024-74276-w.


Cross-modal deep learning model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer.

Guo J, Chen B, Cao H, Dai Q, Qin L, Zhang J NPJ Precis Oncol. 2024; 8(1):189.

PMID: 39237596 PMC: 11377584. DOI: 10.1038/s41698-024-00678-8.


References
1.
von Minckwitz G, Kummel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J . Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst. 2008; 100(8):552-62. DOI: 10.1093/jnci/djn089. View

2.
Lobbes M, Prevos R, Smidt M, Tjan-Heijnen V, Van Goethem M, Schipper R . The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging. 2013; 4(2):163-75. PMC: 3609956. DOI: 10.1007/s13244-013-0219-y. View

3.
Braman N, Etesami M, Prasanna P, Dubchuk C, Gilmore H, Tiwari P . Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res. 2017; 19(1):57. PMC: 5437672. DOI: 10.1186/s13058-017-0846-1. View

4.
Wolff A, Berry D, Carey L, Colleoni M, Dowsett M, Ellis M . Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol. 2008; 26(5):806-13. DOI: 10.1200/JCO.2007.15.2983. View

5.
Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher E . Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16(8):2672-85. DOI: 10.1200/JCO.1998.16.8.2672. View